cms.bioaccessla.com

Category: Preparing for First-In-Human Studies

Offers insights and best practices for Medtech, Biopharma, and Radiopharma companies preparing for their first-in-human clinical trials.

  • FLENI Buenos Aires: The NCT Campus String Is Not the ANMAT File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANMAT, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim FLENI Buenos Aires as a bioaccess® client.

    If you searched FLENI Buenos Aires first-in-human, FLENI Argentina clinical trial, FLENI CRO, or “go direct FLENI Buenos Aires,” you followed a campus string ClinicalTrials.gov still publishes. FLENI in Buenos Aires, Argentina, is a real named neurology-institute string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANMAT file.

    bioaccess®’s position is simple and it is not adversarial: the institute is the site. The First-in-Human CRO still owns ANMAT, accredited ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the institute still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Buenos Aires FLENI campus. It is not Psoriahue CMS 96118, not IDIM CMS 96119, not Centro Medico Arsema (batch 55), and not Instituto Privado Kremer Córdoba. Sharing Buenos Aires / Argentina is not a license to collapse them. FLENI is not Psoriahue. FLENI is not IDIM.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • FLENI (Buenos Aires, Argentina) — canonical NCT string: ALL interventional n=52; DEVICE n=1. Example NCT IDs: NCT07475611.

    Cite canonical ALL n=52 and DEVICE n=1. Do not clone Psoriahue, IDIM, or Arsema onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this institute as a client site.

    That is the leak: a founder searching FLENI Buenos Aires first-in-human finds ALL n=52 (DEVICE n=1) without finding ANMAT. A named institute is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named institute can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the institute can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the institute is not built to own for an investigational device:

    • ANMAT. Argentina’s national medicines and devices authority (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the file a sponsor actually needs. A hallway conversation on this campus is not that file. A published statutory target on the trial side is 90 business days and the clock pauses for RFIs. Trial authorization and commercial registro are separate petitions. A hallway conversation at FLENI is not a Psoriahue file and is not an IDIM file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANMAT actually works (the short version)

    Use live bioaccess® Argentina / ANMAT pages for the full pathway. Trial authorization and commercial registro are different petitions. Do not put both on one Gantt labeled “Argentina.” A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs; ask for a protocol-specific calendar rather than treating an NCT row as start-up.

    Ask for a protocol-specific calendar. A hospital email is not ANMAT clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    FLENI is a serious named Buenos Aires campus on the public registry. ALL n=52 and DEVICE n=1 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANMAT / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract FLENI Buenos Aires directly for a device FIH?

    You can try. The institute can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANMAT applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this institute. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Psoriahue or IDIM Buenos Aires?

    No. Psoriahue is CMS 96118. IDIM is CMS 96119. This page is FLENI only.

    Did bioaccess® run NCT07475611?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. CABA sibling (do not merge): Psoriahue.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Instituto Nacional de Cardiologia Rio de Janeiro: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Instituto Nacional de Cardiologia Rio de Janeiro as a bioaccess® client.

    If you searched Instituto Nacional de Cardiologia Rio de Janeiro first-in-human, INC Rio clinical trial, INC Brazil CRO, or “go direct Instituto Nacional de Cardiologia Rio de Janeiro,” you followed a campus string ClinicalTrials.gov still publishes. Instituto Nacional de Cardiologia in Rio de Janeiro, Brazil, is a real named cardiology-institute string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the institute is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the institute still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Rio de Janeiro INC campus. It is DISTINCT from instituto-nacional-cardiologia-ignacio-chavez-fih (Mexico — different country, different regulator). It is not Oncoclínicas Rio de Janeiro (already live; do not near-dup merge). Sharing an Instituto Nacional de Cardiologia name is not a license to collapse Mexico and Brazil. INC Rio is not Ignacio Chávez. INC Rio is not Oncoclínicas.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Instituto Nacional de Cardiologia (Rio de Janeiro, Brazil) — canonical NCT string: ALL interventional n=52; DEVICE n=4. Example NCT IDs: NCT04766554, NCT04861805, NCT05572736.

    Cite canonical ALL n=52 and DEVICE n=4. Do not clone Ignacio Chávez Mexico or Oncoclínicas Rio onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this institute as a client site.

    That is the leak: a founder searching Instituto Nacional de Cardiologia Rio de Janeiro first-in-human finds ALL n=52 (DEVICE n=4) without finding ANVISA. A named institute is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named institute can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the institute can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the institute is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at INC Rio is not an Ignacio Chávez Mexico file and is not an Oncoclínicas file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Instituto Nacional de Cardiologia Rio de Janeiro is a serious named Brazilian campus on the public registry. ALL n=52 and DEVICE n=4 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Instituto Nacional de Cardiologia Rio de Janeiro directly for a device FIH?

    You can try. The institute can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this institute. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Instituto Nacional de Cardiología Ignacio Chávez or Oncoclínicas Rio?

    No. instituto-nacional-cardiologia-ignacio-chavez-fih is the Mexico campus. oncoclinicas-rio-de-janeiro-fih is already live. This page is Instituto Nacional de Cardiologia Rio de Janeiro only.

    Did bioaccess® run NCT04766554?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Distinct Mexico sibling (do not merge): Instituto Nacional de Cardiología Ignacio Chávez.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Unicamp Campinas: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Unicamp Campinas as a bioaccess® client.

    If you searched Unicamp Campinas first-in-human, Hospital das Clinicas Unicamp clinical trial, Unicamp CRO, or “go direct Unicamp Campinas,” you followed a campus string ClinicalTrials.gov still publishes. Unicamp in Campinas, Brazil, is a real named university-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the university is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Campinas Unicamp campus (alias includes Hospital das Clinicas da Unicamp). It is not university-of-campinas-fih if already live under a different fold, not Hospital Celso Pierro Campinas (already live), not Loema Instituto Pesquisa Campinas, and not Centro Pesquisa São Lucas Campinas. Sharing Campinas is not a license to collapse them. Unicamp is not Celso Pierro. Unicamp is not Loema.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Unicamp (Campinas, Brazil) — canonical NCT string: ALL interventional n=147; DEVICE n=2. Example NCT IDs: NCT04171063, NCT05017636.

    Cite canonical ALL n=147 and DEVICE n=2. Do not clone Celso Pierro, Loema, or São Lucas Campinas onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site.

    That is the leak: a founder searching Unicamp Campinas first-in-human finds ALL n=147 (DEVICE n=2) without finding ANVISA. A named university campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named university can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the university can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the university is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at Unicamp is not a Celso Pierro file and is not a Loema file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Unicamp is a serious named Campinas campus on the public registry. ALL n=147 and DEVICE n=2 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Unicamp Campinas directly for a device FIH?

    You can try. The university can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this university. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Hospital Celso Pierro or Loema Campinas?

    No. Hospital Celso Pierro Campinas and Loema Instituto Pesquisa Campinas are already live on their own slugs. This page is Unicamp only.

    Did bioaccess® run NCT04171063?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Campinas sibling (do not merge): Hospital Celso Pierro Campinas.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Hospital de Base São José do Rio Preto: The NCT Campus String Is Not the ANVISA File

    Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Hospital de Base São José do Rio Preto as a bioaccess® client.

    If you searched Hospital de Base Sao Jose do Rio Preto first-in-human, Hospital de Base SJRP clinical trial, Hospital de Base Rio Preto CRO, or “go direct Hospital de Base São José do Rio Preto,” you followed a campus string ClinicalTrials.gov still publishes. Hospital de Base in São José do Rio Preto, Brazil, is a real named hospital-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

    bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named São José do Rio Preto Hospital de Base campus. It is DISTINCT from hospital-de-base-distrito-federal-brasilia-fih (Brasília / Distrito Federal — different city, different campus). It is not FAMERP São José do Rio Preto (already live). Sharing a Hospital de Base name is not a license to collapse Brasília and São José do Rio Preto. SJRP Hospital de Base is not Brasília Hospital de Base.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

    Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Hospital de Base (São José do Rio Preto, Brazil) — canonical NCT string: ALL interventional n=210; DEVICE n=1. Example NCT IDs: NCT04701684.

    Cite canonical ALL n=210 and DEVICE n=1. Do not clone Hospital de Base Distrito Federal Brasília onto this slug.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.

    That is the leak: a founder searching Hospital de Base São José do Rio Preto first-in-human finds ALL n=210 (DEVICE n=1) without finding ANVISA. A named hospital campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the hospital can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the hospital is not built to own for an investigational device:

    • ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at Hospital de Base São José do Rio Preto is not a Brasília Distrito Federal Hospital de Base file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. We will not invent a campus-only premium here.
    • ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How ANVISA actually works (the short version)

    Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

    Do not smear the hospital

    Hospital de Base São José do Rio Preto is a serious named Brazilian campus on the public registry. ALL n=210 and DEVICE n=1 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Hospital de Base São José do Rio Preto directly for a device FIH?

    You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the studies.

    Is this the same page as Hospital de Base Distrito Federal Brasília?

    No. hospital-de-base-distrito-federal-brasilia-fih is already live for the Brasília campus. This page is Hospital de Base São José do Rio Preto only — different city.

    Did bioaccess® run NCT04701684?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Distinct Brasília sibling (do not merge): Hospital de Base Distrito Federal Brasília.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Centralized vs decentralized ethics review across Latin American clinical trials

    Not every Latin American country runs clinical-trial ethics the same way. Some markets clear institutional research ethics committees (RECs) in weeks. Others stack a national health-authority desk on top of — or instead of — the hospital committee. Treating “LATAM ethics” as one bottleneck is how a US MedTech startup mis-prices a first-in-human calendar by 60–90 days.

    I am Julio Martinez-Clark, CEO of bioaccess®. This page is the ethics-architecture cut: institutional versus centralized review, where parallel submission is real, and how that should change country pick for FIH versus feasibility versus pivotal work. Clocks below are already published on country hubs and FIH guides — not new invented medians.

    Two architectures, not one “LATAM IRB”

    Institutional / Type II committee first. A CNBI-registered or nationally accredited hospital or network committee reviews the protocol, consent, and investigator packet. The national authority may run in parallel or after, depending on the statute.

    Centralized / multi-tier. A national ethics or health-research desk is on the critical path before first patient — sometimes after local review, sometimes as the primary gate. Startup time stretches when you serialize desks that the statute allows to run together.

    The myth to retire: every LATAM country waits on the same centralized government bottleneck. The operator question is which desks are parallel and which are serial.

    Country snapshots sponsors actually use

    Panama — parallel MINSA + Type II ethics

    Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C) put clinical trials on Type II-accredited committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Ordinary ethics review is capped at 20 business days. High-risk protocols — Class III implants and novel biomaterials — get parallel MINSA + ethics, not a forced serial queue. RESEGIS registration before start; standard projects get a registration receipt in three business days. Practitioner ethics band already on the hub: 3–5 weeks, with MINSA clearance available concurrently on the high-risk track. See Panama Class III FIH and the Decreto 21 explainer.

    Dominican Republic — institutional REC speed on a DIGEMAPS file

    The Dominican Republic is a lead first-in-human jurisdiction for bioaccess®. Local research ethics committee review sits with the site; the national health-authority file (DIGEMAPS / CONABIOS path as published on the CRO in Dominican Republic page) is a separate operating problem. Do not confuse a fast institutional REC letter with a complete national authorization package — and do not invent a CONABIOS median that is not on the live page.

    El Salvador — DNM/SRS as the trial desk

    El Salvador is a published lead FIH geography under DNM/SRS. Trial authorization and ethics sit on that country’s rulebook (Acuerdo 838 BIS and related instruments already cited in our regulatory notes). Use the published 30–60 day trial-authorization band from the FIH cost page — not a new clock here. See Panama / El Salvador FIH cost vs US.

    Colombia — ethics plus INVIMA CTA (new FIH not recommended)

    Colombia still has institutional CEI/IRB review and an INVIMA clinical-trial authorization track under the published decree/resolution stack (Decreto 4725/2005; Res. 2378/2008 and related). Commercial INVIMA registro remains a core bioaccess® market-access service. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new first-in-human trial execution. Keep ethics speed and INVIMA CTA risk on separate lines in the budget.

    Brazil — CEP then CONEP / ANVISA for many device paths

    Brazil’s ethics architecture is multi-tier for a large share of interventional research: local CEP review, with CONEP involvement when the study type requires it, plus ANVISA on the regulatory side. That is a serialized or partially overlapping national stack — plan months, not the Panama 3–5 week ethics band. Use ANVISA/CEP guidance already on Brazilian market-access and trial pages; do not paste a Panama clock onto a Brazilian FIH.

    Mexico — COFEPRIS and institutional review

    Mexico pairs institutional ethics with COFEPRIS authorization for many investigational and commercial paths. COFEPRIS vía abreviada and holder/IOR rules are commercial-registration facts (see the Mexico COFEPRIS holder page). For trials, treat COFEPRIS as a national desk on the critical path — not an institutional REC-only country.

    Chile — ISP and institutional ethics

    Chile runs institutional ethics with ISP (Instituto de Salud Pública) on the sanitary/clinical side under the published Código Sanitario / ISP resolution stack. Recent registration waves (including Decreto Exento N° 25 of 2026 on the commercial side) do not erase the trial/ethics split. Use Chile country pages for study-specific clocks; do not invent a national ethics median here.

    Parallel submission: where 60–90 days come from

    The savings appear when you stop serializing desks the statute allows to run together:

    • Panama high-risk: open MINSA and Type II ethics in parallel; register in RESEGIS before start.
    • Import file: start insurance, Spanish IB, and import permit drafting while ethics is open — not after the stamp.
    • Site contracts: do not wait for the national letter to begin CTA negotiation when the site will accept a parallel pack.

    Serialize only when the law requires it (many Brazilian and some Mexican paths). Forcing serial review in a parallel country is a self-inflicted quarter.

    Match architecture to clinical phase

    • FIH / early feasibility (small n). Prefer markets with institutional or parallel Type II review and published short ethics bands — Panama and El Salvador as lead examples on our hubs. Design the file for 21 CFR 812.28 inspectability from day one.
    • Feasibility / expansion cohorts. Add a second country only when enrollment or indication density requires it — keep ethics architectures compatible so monitoring and AE dictionaries stay one system.
    • Pivotal / multi-country. Budget for centralized desks (Brazil, parts of Mexico) and do not price the whole program on a Panama ethics band.

    One-page gate before you pick the country

    1. Which desks are on the critical path? Institutional only, parallel national + ethics, or serialized national.
    2. Is parallel submission written into the statute or decree? Panama Decreto 21 high-risk is yes. Do not assume the same elsewhere.
    3. Spanish packet ready? Protocol, IB, consent, insurance — foreign-language drafts do not substitute.
    4. US filing intended? If yes, ethics speed without 812.28 documentation is a false economy.
    5. Colombia new FIH? Default no for new first-in-human execution; yes for commercial registro conversations.

    If you are choosing between Panama, El Salvador, the Dominican Republic, Chile, or a multi-country plan, send bioaccess® the protocol stage, device risk class, intended US filing, and target first-patient month. We will map the ethics desks — not a brochure “LATAM IRB” average.

    Related: clinical trials, market access, and Australia vs Latin America for FIH.

  • FDA 21 CFR 812.28 in LATAM: foreign clinical trial inspectability for device sponsors

    FDA’s foreign clinical data rule is not a slogan. Under 21 CFR 812.28, the agency can use a well-designed, well-conducted investigation outside the United States to support an IDE or a device marketing application — and it can also show up at the site to validate the file. The question US MedTech teams should ask before first patient in Latin America is not “will FDA accept OUS data?” It is “could an English-speaking inspector reconstruct what happened here?”

    I am Julio Martinez-Clark, CEO of bioaccess®. This page is the inspectability cut of 812.28 for LATAM device trials. For the IDE-package framing, use Can OUS first-in-human data support an FDA IDE submission?. For country clocks, use the published Panama and El Salvador hubs — not a new timeline invented here.

    What 812.28 actually requires

    Section 812.28 (final rule, 83 FR 7386, 21 February 2018) says FDA will accept foreign clinical information for an IDE or a device marketing application (PMA, HDE, 510(k), or De Novo) when three conditions are met:

    1. Good clinical practice. Design, conduct, monitoring, auditing, recording, analysis, and reporting that keep data credible and protect subjects — including independent ethics-committee review before initiation, continuing review, and documented freely given informed consent. FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28 (already on our FDA acceptance guide). Investigations initiated on or after 21 February 2019 must conform to the 2018 foreign-data framework.
    2. Supporting information in 812.28(b). For a significant-risk device under 812.3(m), submit the full (b) set: investigators and sites; protocol and results; a statement that the investigational device is identical to the US device or a detailed comparison; valid scientific evidence under 21 CFR 860.7 if you claim safety and effectiveness; IEC identity meeting 812.3(t); consent, monitoring, and investigator GCP training.
    3. Inspectability. FDA can validate the data through an onsite inspection or other appropriate means if the agency deems it necessary. A LATAM file that cannot be inspected is not an 812.28 file.

    Section 812.28(e) is the residual clause: even when a foreign study does not fully meet paragraph (a), FDA may still accept the information if it believes the data are credible and accurate and that subject rights were adequately protected. Do not plan to live in (e). Build (a).

    The failure mode I see: ethics approval without an inspectable record

    Sponsors who only chase local ethics-committee approval treat the stamp as the finish line. That buys enrollment speed. It does not buy an IDE conversation.

    Three patterns burn the file:

    • Source that cannot be reconstructed. Paper charts in a language and filing system nobody planned to reconcile. When the IDE questions arrive, you cannot show who saw what, when.
    • Device accountability that dies at customs. Investigational units imported through a commercial distributor “because they already import,” with no chain that survives explant, quarantine, and an English-speaking inspector.
    • Consent written in English and “translated later.” 812.28 wants documented consent the IEC actually approved. For FDA use, include the 21 CFR 50.25 elements. Spanish first.

    Those are the same failure modes already named on the OUS-IDE page. Inspectability is the operational layer underneath them.

    What “inspection-ready” means at a LATAM site

    Architect the study so an FDA inspector (or a CRO monitor acting for a later US filing) can walk the site without a scavenger hunt:

    • Electronic data capture with audit trails, not spreadsheet science.
    • Source documents that map to CRF fields in a single reconciliation plan — imaging, device logs, AE narratives.
    • Device accountability from import permit through implant/explant that matches the investigator brochure identity claim in 812.28(b)(5).
    • Monitoring reports that show who visited, what was queried, and what closed — not a one-page “visit done.”
    • Investigator GCP training on file before first procedure, not after the first query.
    • eTMF structure that an English-speaking reviewer can navigate: protocol versions, IEC approvals, consents, safety letters, delegation logs.

    Panama’s Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C) already puts high-risk protocols through parallel MINSA + Type II ethics review, RESEGIS registration before start, and 24-hour / 15-day serious-adverse-event clocks. That decree structure helps the local file. It does not replace the 812.28 inspectability design. Same rule for El Salvador under DNM/SRS and for any other lead FIH geography we publish: local authorization is necessary; FDA-usable documentation is a separate design choice.

    Site selection is an inspectability decision

    Pick sites and principal investigators who have already run device protocols with monitors in the room. Early-feasibility n in Panama City is typically 5–20 patients — the right size for a Class III first-in-human cohort (already on the Panama Class III FIH page). Rare disease or a larger n belongs in a multi-country plan.

    Public programs already on the FDA-acceptance guide show the pattern: Axoft FINESSE (first cases at The Panama Clinic; FDA Breakthrough Device Designation in 2022); Newrotex (ethics approval in Panama; FDA Pre-Sub for a 510(k) using LATAM data); ReGelTec HYDRAFIL (Colombia early-feasibility, then FDA IDE for a US pivotal). Those names are already public. I am not adding unpublished sponsors or devices under development.

    Colombia remains a core market-access geography. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new first-in-human trial execution. Keep commercial registro and investigational CTA tracks apart.

    Pre-Sub before you lock endpoints

    If the LATAM protocol is meant to support a later US IDE, file a Q-Sub / Pre-Sub before you lock endpoints (written feedback in 75 calendar days — already on the FDA-acceptance guide). Endpoints and inclusion criteria have to be relevant to the intended US population; site standard of care has to be comparable to US practice. Changing the device after first implant without a comparability memo makes 812.28(b)(5) unforgiving.

    One-page gate before first patient

    1. US filing intended. IDE, 510(k), De Novo, PMA, or HDE — named before country pick.
    2. Device identity claim. Identical to the US unit, or a written comparison with change control.
    3. IEC + local authority path. Type II / national desk as the country requires — not an ad-hoc hospital chat.
    4. Spanish consent with 21 CFR 50.25 elements if FDA use is the plan.
    5. EDC + eTMF + device accountability that survive an English-speaking inspector.
    6. Monitoring plan with query closure ownership before first implant.

    If you are staring at a LATAM first-in-human calendar and a future FDA conversation, send bioaccess® the protocol stage, device risk class, intended US filing, and whether the investigational unit is identical to the US unit. We will tell you whether the file is being built for 812.28(a) or for a case series.

    Related: FIH without waiting years for FDA, clinical trials, and the LATAM site network.

  • FIH cost in Panama or El Salvador vs the US: use published clocks, not invented averages

    Boards ask a cost question that is really a calendar question: how much does a first-in-human medical device trial in Panama or El Salvador cost versus the United States? The honest answer is not a single invoice line. It is which clock you are buying — evidence versus domestic site contracting — and which numbers are already published on bioaccess® country hubs versus numbers nobody should invent on a blog.

    I am Julio Martinez-Clark, CEO of bioaccess®. This page uses only figures and clocks already live on bioaccessla.com. It is not a quote. Confirm study-specific budgets with a proposal.

    What “vs the US” usually means

    When founders say the U.S. FIH is “too expensive,” they often mean three stacked costs:

    • Time to first patient — site contracting, IRB sequencing, and treating first implant as a United States-only problem. That is the year the FIH-without-waiting-for-FDA article already names — not the 30-day IDE review clock alone.
    • Per-patient and site economics — published LATAM bands versus a U.S. academic stack you have not actually bid yet.
    • Evidence quality for later FDA use — ISO 14155 discipline and 21 CFR § 812.28 design, or you bought cheap subjects you cannot spend.

    A Latin America investigation is not a discount coupon on FDA. It is a second evidence calendar that can run while the U.S. path is still being built.

    Published Panama clocks and bands

    Panama is a published lead Class III FIH geography under MINSA and the Comité Nacional de Bioética de la Investigación (CNBI), on Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 — already detailed on the Panama Class III FIH guide.

    • Ethics band already published on country comparisons: Panama ethics about 3–5 weeks versus Colombia about 4–6 weeks (live comparison cited on Dominican Republic and Colombia holder pages that point at clinical-trials-panama).
    • Per-patient band already published: about USD 12,000–22,000 per patient in Panama versus about USD 15,000–25,000 in Colombia on that same published comparison. Those are hub figures, not a new tariff invented here.
    • Dollarized economy, English-capable sites, investigation units only — commercial registro stays a separate MINSA market-access file. Do not put a selling license number on FIH freight.

    I will not invent a “typical U.S. per-patient” dollar figure on this page. If your U.S. sites have not returned a real budget, you do not have a US comparator — you have a hope.

    Published El Salvador clocks

    El Salvador’s public study-startup language is a 30–60 day band for CNEIS ethics plus SRS clinical-investigation authorization. That band is not a DNM/SRS commercial registro. The sibling post on CNEIS/SRS trial vs DNM registro exists because sponsors keep merging the two clocks and then “comparing cost” against a U.S. IDE that was never the same petition.

    Cost discipline in El Salvador starts with keeping the investigation file off the commercial holder track. Mixing them creates rework that erases any calendar advantage.

    What to put in the board slide (instead of one fake total)

    1. Evidence column. Lead FIH jurisdiction (Panama MINSA/CNBI or El Salvador CNEIS/SRS), ethics desk, investigational importer, § 812.28 owner, ISO 14155 TMF owner.
    2. Published LATAM bands only. Use the Panama per-patient and ethics figures above when Panama is in scope. Ask for a study-specific quote before you present a single program total.
    3. U.S. column as real bids. Site budgets, IRB fees, and contracting lead times from named U.S. sites — or leave the cell blank. Blank is more honest than a blogger’s invented US average.
    4. Commercial column (optional). Holder / IOR countries on the market-access hub. Already-cleared launch is a different SKU from FIH.

    Where “cheap LATAM” burns money

    • Thin TMF. Speed without ISO 14155 monitoring, device accountability, and ethics correspondence buys investor slides and FDA friction.
    • One Gantt bar for FIH and registro. El Salvador’s 30–60 day language is the clearest public warning.
    • Country tourism. Five ethics desks because a slide said “LATAM” dilutes the file.
    • Invented US baselines. Comparing Panama’s published USD 12K–22K band to a made-up “US is $80K” number is not diligence.

    Colombia note (do not flip the public line)

    Colombia remains a strong market-access geography and a historical FIH geography for bioaccess®. The public line still stands: INVIMA clinical-trial approval timelines have become unpredictable, so bioaccess® does not currently recommend Colombia for new first-in-human execution. Use Panama, El Salvador, Chile, or the Dominican Republic when the protocol needs a lead investigation desk — and keep INVIMA registro on the commercial track.

    Insurance and import are line items, not optional footnotes

    Ethics packets in Panama and El Salvador still want financial responsibility for participant injury documented before initiation — Spanish certificate language is the usual ask. That is a coverage exhibit, not a product-liability rider someone forwarded from a U.S. policy. The live insurance intercepts already warn that a master excluding the country fails ethics, and that product liability is not clinical-trial liability. Budget the certificate with the CRO and a licensed broker before you present “LATAM is cheaper.”

    Investigational import is another line that disappears from naive US-vs-LATAM spreadsheets. Name the importer for investigation units. Do not put a cousin commercial registro number on FIH freight — that pattern burns weeks at customs and contaminates both tracks. The parallel-calendar article already lists that failure mode; cost models that ignore it are fiction.

    How bioaccess® talks about program-level savings

    Across Latin America FIH hubs, bioaccess® has long published experience-based language of roughly 30% lower program cost and about 40% faster versus typical US/EU baselines since 2010 — as experience, not a formal study (already on Dominican Republic and LATAM FIH benchmark language). Treat that as orientation, not a guarantee for your Class III implant with a thin TMF. Study-specific quotes beat blog averages.

    Practical next step

    This week, rewrite the cost slide as three columns: published LATAM evidence calendar, real U.S. site bids (or blank), commercial holder countries if any. Start from the Panama Class III FIH guide or the El Salvador clinical-trials hub for column one. If you need a study-specific number, bring protocol stage, device class, and sample size — bioaccess® will quote the investigation without inventing a U.S. average to win the comparison.

  • Reina Madre Mexico City: The NCT Facility String Is Not the COFEPRIS File

    Reina Madre Mexico City: The NCT Facility String Is Not the COFEPRIS File

    Reina Madre in Mexico City, Mexico, is a separate named facility string in the public record.

    General information, not legal or regulatory advice. This page cites a public ClinicalTrials.gov facility row. It does not claim that bioaccess® ran the study, that the facility is a client, or that the registry record is a first-in-human device authorization.

    When a sponsor searches a facility name, the search result can look like a complete clinical-development answer. It is not. A site can contribute investigators, rooms, coordinators, recruitment, and protocol-specific operations. The sponsor still needs the study strategy, contracts, ethics submission, data systems, monitoring, safety reporting, insurance, and the applicable regulatory file. A facility string is not a CRO.

    The public record used here is ClinicalTrials.gov study NCT06581068. The record describes an industry-sponsored study involving IVF-lab automation and lists facilities in Mexico City. The registry is evidence that the facility string appears in a public study record. It is not evidence of a bioaccess® engagement, an endorsement, a completed outcome, or a regulatory clearance.

    What the facility can do

    • Assess whether the protocol fits its patient flow, laboratory capability, staffing, and local research procedures.
    • Discuss investigator interest, site feasibility, visit logistics, and institutional review steps.
    • Provide site-specific costs and operational requirements for the work it will physically perform.

    What the facility row does not establish

    • It does not establish that the facility is the sponsor, CRO, importer of record, insurer, or regulatory applicant.
    • It does not establish the identity or qualifications of a principal investigator beyond whatever the public record itself displays.
    • It does not establish that a treatment-validation study is a first-in-human medical-device study.
    • It does not replace a protocol-specific feasibility review, agreement, or regulatory assessment.

    Mexico City is a site decision, not the whole start-up plan

    For work in Mexico, a sponsor should separate institutional ethics and operational planning from the COFEPRIS pathway. Trial authorization, investigational import, insurance, monitoring, electronic data capture, adverse-event reporting, and the later sanitary registration question are different workstreams. A site email can help answer a local feasibility question. It cannot by itself open the national file or create a quality system.

    bioaccess® can assess the country and protocol fit, coordinate the regulatory and site-start-up work, and keep the operating responsibilities explicit. The correct sequence is to confirm the protocol, identify the required site capabilities, document feasibility, agree the scope, and then activate the facility if it fits. The page is not a claim that either named facility is a signed bioaccess® partner.

    About the registry record

    NCT06581068 is cited here because it is the public source for the facility association. Registry records can change, use facility aliases, and describe a study purpose that is not the same as a sponsor’s later device-regulatory plan. Read the current record directly before making a decision. Do not infer clinical performance, patient outcomes, regulatory status, or commercial availability from a facility name.

    Frequently asked questions

    Did bioaccess® run NCT06581068?

    No. This page cites a public facility row only. We will not invent a client relationship, investigator role, outcome, or sponsor claim.

    Can a sponsor contract the facility directly?

    A sponsor can discuss site interest and local operations with a facility. That discussion is not a substitute for the CRO, regulatory, safety, data, insurance, and multi-country responsibilities the protocol may require.

    Is this a regulatory approval?

    No. A ClinicalTrials.gov listing is not COFEPRIS authorization, ethics approval, import permission, or sanitary registration.

    What is the next step?

    Start with a protocol-specific feasibility and country-fit review. Then define the regulatory, site, monitoring, data, safety, insurance, and import workstreams before activation.

    bioaccess® does not name either facility as a signed partner here. We use the public record to answer a search, not to invent a relationship.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • New Hope Fertility Centre Mexico City: The NCT Facility String Is Not the COFEPRIS File

    New Hope Fertility Centre Mexico City: The NCT Facility String Is Not the COFEPRIS File

    New Hope Fertility Centre in Mexico City, Mexico, is a named facility string in the public record.

    General information, not legal or regulatory advice. This page cites a public ClinicalTrials.gov facility row. It does not claim that bioaccess® ran the study, that the facility is a client, or that the registry record is a first-in-human device authorization.

    When a sponsor searches a facility name, the search result can look like a complete clinical-development answer. It is not. A site can contribute investigators, rooms, coordinators, recruitment, and protocol-specific operations. The sponsor still needs the study strategy, contracts, ethics submission, data systems, monitoring, safety reporting, insurance, and the applicable regulatory file. A facility string is not a CRO.

    The public record used here is ClinicalTrials.gov study NCT06581068. The record describes an industry-sponsored study involving IVF-lab automation and lists facilities in Mexico City. The registry is evidence that the facility string appears in a public study record. It is not evidence of a bioaccess® engagement, an endorsement, a completed outcome, or a regulatory clearance.

    What the facility can do

    • Assess whether the protocol fits its patient flow, laboratory capability, staffing, and local research procedures.
    • Discuss investigator interest, site feasibility, visit logistics, and institutional review steps.
    • Provide site-specific costs and operational requirements for the work it will physically perform.

    What the facility row does not establish

    • It does not establish that the facility is the sponsor, CRO, importer of record, insurer, or regulatory applicant.
    • It does not establish the identity or qualifications of a principal investigator beyond whatever the public record itself displays.
    • It does not establish that a treatment-validation study is a first-in-human medical-device study.
    • It does not replace a protocol-specific feasibility review, agreement, or regulatory assessment.

    Mexico City is a site decision, not the whole start-up plan

    For work in Mexico, a sponsor should separate institutional ethics and operational planning from the COFEPRIS pathway. Trial authorization, investigational import, insurance, monitoring, electronic data capture, adverse-event reporting, and the later sanitary registration question are different workstreams. A site email can help answer a local feasibility question. It cannot by itself open the national file or create a quality system.

    bioaccess® can assess the country and protocol fit, coordinate the regulatory and site-start-up work, and keep the operating responsibilities explicit. The correct sequence is to confirm the protocol, identify the required site capabilities, document feasibility, agree the scope, and then activate the facility if it fits. The page is not a claim that either named facility is a signed bioaccess® partner.

    About the registry record

    NCT06581068 is cited here because it is the public source for the facility association. Registry records can change, use facility aliases, and describe a study purpose that is not the same as a sponsor’s later device-regulatory plan. Read the current record directly before making a decision. Do not infer clinical performance, patient outcomes, regulatory status, or commercial availability from a facility name.

    Frequently asked questions

    Did bioaccess® run NCT06581068?

    No. This page cites a public facility row only. We will not invent a client relationship, investigator role, outcome, or sponsor claim.

    Can a sponsor contract the facility directly?

    A sponsor can discuss site interest and local operations with a facility. That discussion is not a substitute for the CRO, regulatory, safety, data, insurance, and multi-country responsibilities the protocol may require.

    Is this a regulatory approval?

    No. A ClinicalTrials.gov listing is not COFEPRIS authorization, ethics approval, import permission, or sanitary registration.

    What is the next step?

    Start with a protocol-specific feasibility and country-fit review. Then define the regulatory, site, monitoring, data, safety, insurance, and import workstreams before activation.

    bioaccess® does not name either facility as a signed partner here. We use the public record to answer a search, not to invent a relationship.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Dr. Juan Osorio, Chondrograft FIH Principal Investigator in Panamá: The Named PI Is Not the MINSA File

    Figures cited from the PR Newswire release “Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study” (2 September 2026, 16:58 ET), the live ClinicalTrials.gov record NCT07542184 (last update posted 21 August 2026; first posted 21 April 2026), and published bioaccess® Panama pages, verified 3 September 2026. General information, not legal or regulatory advice. Confirm current MINSA, CNBI, and FDA rules with qualified advisers. We name only the investigators, facility, and trial those sources support, and we do not reprint site contact emails or phone numbers. Nanochon is not claimed as a bioaccess® client. bioaccess® is not listed on this NCT and did not run this study.

    If you searched Dr. Juan Osorio Panamá, Juan Osorio principal investigator Chondrograft, Emilio Tufiño knee cartilage trial, Nanochon first case Panamá, or “go direct to the surgeon,” you followed an investigator string that public press and ClinicalTrials.gov both publish. Dr. Juan Osorio is a real named principal investigator. He is not the operator of the MINSA file.

    bioaccess®’s position is simple and it is not adversarial: the investigator is the investigator and the hospital is the site. The First-in-Human CRO still owns MINSA / CNBI, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if Panamá is not the only fit. Sponsors who skip the CRO and email the surgeon still have to rebuild that stack. A principal-investigator line does not become a CRO.

    This is a person-string intercept, and it exists only because the building already has its own page. The facility intercept stays at The Panama Clinic (Spanish: versión en español), and the distinct legal-entity string stays at CEVAXIN / The Panama Clinic. This page does not clone clinical trials in Panama. That page stays the country operating system.

    Why the surgeon’s name wins the search — and why that is not a CRO

    On 2 September 2026, Nanochon announced the successful treatment of the first patient in its First-in-Human study of Chondrograft™, a 3D-printed implant for articular cartilage defects of the knee. Per that release: Dr. Juan Osorio and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. Dr. Osorio is quoted in the release identifying himself as the Principal Investigator for the study. Dr. Tufiño is quoted describing the procedure as “bone-sparing, minimally invasive, and streamlined.” The release also states that Nanochon plans a Level 1 multi-center, randomized, controlled pivotal trial after the FIH study, and that Chondrograft™ has FDA Breakthrough Device Designation. No CRO is named anywhere in that release.

    The registry says the same thing in registry language. NCT07542184 — brief title: Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) – Panama. Official title: A First in Human (FIH) Early Feasibility Study (EFS) to Evaluate the Safety and Performance of the Nanochon Chondrograft™ Implant for Re-surfacing of Cartilage Lesions. Organization study ID: 101-2024 – PAN. Lead sponsor: Nanochon, Inc., class INDUSTRY, responsible party the sponsor. No collaborator is listed. No CRO is listed.

    Design on the 3 September 2026 snapshot: interventional; single-group; no masking; primary purpose treatment; phase N/A; estimated enrollment 5. Actual start 30 July 2026; estimated primary completion and completion September 2027. Study first posted 21 April 2026; last update posted 21 August 2026 — that is, before the 2 September first-case announcement. Status RECRUITING. Condition: knee cartilage lesions, with registry keywords for medial and lateral femoral condyle and trochlear articular cartilage lesions. Intervention: a device — mini-arthrotomy or arthroscopic surgical implantation of the Nanochon Chondrograft. Eligibility: male or female aged 22–60, MRI knee evaluation within six months, able to read and speak English and/or Spanish, and voluntary signature of the REB-approved informed consent.

    The single Panama location row is The Panama Clinic, Panama City, Provincia de Panamá, RECRUITING, with Juan Osorio, MD listed as PRINCIPAL_INVESTIGATOR. That is the registry’s own field, not our inference. A sister Canadian record, NCT07249489 (same official title, org study ID 101-2024-CAN, estimated n=10, NOT_YET_RECRUITING, last update posted 2 September 2026), lists University of British Columbia in Vancouver and an Orthopaedic Clinic in Toronto. Canada is outside the Latin American geography this page covers; we note it so nobody merges the two records.

    Read the two sources together. An estimated five patients, a 3D-printed implant, a Breakthrough-designated device, a planned pivotal RCT to follow — and the only human names a sponsor can find are two surgeons and a company CEO. That is the site-direct leak in its purest form: the search resolves to a person, and the person is not the operator of the file.

    The investigator is the investigator. The CRO is the operator.

    A regenerative sports-medicine surgeon in Panama City can carry the procedure, the surgical judgement, the follow-up exams, and the source documents. That is necessary, and on this program it is clearly working — the first case was enrolled and treated quickly enough that the sponsor made a point of it. It is still not the same job as owning a first-in-human file.

    What a named investigator and their hospital can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and surgical feasibility for a cartilage protocol — when that service is available and appropriate for your device, which is not automatic.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote procedure, theatre, and local staffing costs for the cases they will physically perform.

    What an investigator is not built to own for an investigational device:

    • MINSA and the CNBI. The national file and the national bioethics pathway are not a hallway conversation with a surgeon.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit, end to end. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. The published bioaccess® Panama planning band is $5,000–$15,000 depending on device risk and enrollment. That is a published planning band, not a quote for this study.
    • ISO 14155 monitoring, EDC, adverse-event reporting, and the TMF — across Panamá and any second country.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after the GCP and ethics documentation that rule defines. Eligibility is not clearance. See OUS FIH and FDA IDE.
    • Multi-country optionality. A five-patient EFS that is meant to feed a Level 1 pivotal trial is exactly when one surgeon’s calendar stops being the plan.

    Going direct to Dr. Osorio is how you confirm a surgeon. It is not how you open an investigational file.

    Investigator versus CRO

    Workstream What the named investigator and hospital typically own What the CRO still owns
    Procedure Mini-arthrotomy or arthroscopic implantation, imaging, follow-up exams Protocol fit, training, implant accountability
    Ethics Institutional committee calendar and local rules Packet, ICF, IB alignment, deficiency cycle
    National authority Not the permit holder by being named as PI MINSA / CNBI file
    Import Receiving and storage if contracted Importer of record for the investigational implant
    Quality Source documents from the cases performed ISO 14155 monitoring, EDC, AE reporting, TMF
    FDA conversation Clinical judgement and case data 21 CFR 812.28 narrative — eligibility, not clearance
    Scale-up One surgical team in Panama City Second country, pivotal readiness, Colombia (INVIMA) and the rest of the platform

    What the Nanochon public file actually supports — and what it does not

    • Device: Chondrograft™, a 3D-printed implant for focal articular cartilage defects of the knee, with FDA Breakthrough Device Designation per the company release.
    • Sponsor: Nanochon, Inc. (industry). No collaborator on the NCT. No CRO named in the release or on the record.
    • Site: The Panama Clinic, Panama City — the only Panama location row, RECRUITING. Already intercepted on its own page.
    • Named investigators (as published): Juan Osorio, MD — principal investigator on the NCT row and self-identified as PI in the 2 September release; Emilio Tufiño, MD — named in the release as performing the first procedure. We do not merge them into a single identity and we do not add a third name.
    • Milestone: first patient treated, announced 2 September 2026. Actual study start on the registry is 30 July 2026.
    • Not claimed here: that bioaccess® ran this study or is on this NCT; that Nanochon is a bioaccess® client; that we have Chondrograft outcomes; that Breakthrough Device Designation is clearance or approval; that the Panama and Canada records are one study.

    What the CRO still does after you have a surgeon’s name

    • Regulatory-fit, not tourism. Panamá is a lead first-in-human jurisdiction on the published platform. It is not automatically the right country for every indication. bioaccess® still runs clinical trials in Colombia and the rest of the platform.
    • Protocol, IB, ICF, insurance, and the MINSA / CNBI packet.
    • Importer of record and implant accountability.
    • ISO 14155 monitoring and the 21 CFR 812.28 narrative for the FDA conversation that a Breakthrough-designated implant will eventually need.
    • Optionality when a five-patient EFS has to become a multi-centre pivotal study.

    The founder podcast, when a conversation needs a voice, is Global Trial Accelerators™. Background: LATAM FIH hospitals vs the CRO.

    Frequently asked questions

    Why is there a page for a person rather than only for the hospital?

    Because sponsors search the string they see, and the 2 September release put two surgeons’ names in front of the building. The facility page already exists at The Panama Clinic, and the legal-entity page exists at CEVAXIN. This page answers the investigator query and links back rather than duplicating either one.

    Can I contract Dr. Osorio directly?

    You can try. A principal investigator can discuss surgical feasibility, institutional ethics calendars, and local case costs. He cannot become your MINSA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager because a press release named him. Contract the CRO; let the CRO activate the site and the investigator.

    Did bioaccess® run the Chondrograft first-in-human study?

    No. No public bioaccess® page says so, bioaccess® is not on NCT07542184, and we will not invent that relationship. This page intercepts the search; it does not claim the study.

    Does Breakthrough Device Designation mean the implant is approved?

    No. The company release states the designation; a designation is a review-interaction pathway, not clearance or approval. A first-in-human EFS is still an investigational study, and foreign data still has to meet 21 CFR 812.28 conditions to be eligible for FDA submission and review.

    Is Colombia still an option?

    Yes. bioaccess® still runs trials in Colombia. A Panamá investigator search is not an instruction to abandon INVIMA. See CRO in Colombia.